On November 21, Abivax S.A. rose 4.46% in After-Hours Trading to $74.8/share, with turnover of $837,400.
The move followed the company’s response to a short report published on November 20, stating that the report contained inaccurate and misleading claims and reaffirming the integrity of its clinical development program and Phase 3 ABTECT trial results in ulcerative colitis.
Earlier in Regular Trading, the stock had fallen after Wedbush lowered its price target to $96 from $118 while maintaining a neutral rating. That context highlights how the company’s formal rebuttal appears to have eased some of the pressure tied to the short-seller attack. Abivax S.A.’s lead candidate, obefazimod, is in Phase 3 development for moderately to severely active ulcerative colitis and is also being developed for Crohn’s disease.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)